| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 1.7K | 0.0% | 9.1% |
| Total Income | 1.8K | 0.2% | 9.8% |
| Expenditure | 1.6K | 9.4% | 10.5% |
| PBT | 180.50 | 43.6% | 65.5% |
| Net Profit | 122.20 | 50.0% | 70.1% |
| OPM | 13.67% | 7.91pp | 15.24pp |
| NPM | 6.93% | 6.89pp | 14.01pp |
| EPS | 8.05 | 50.0% | 70.2% |
Cycle trough with innovation, but margin & PAT miss hard
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Prior guidance 'FY27 better than FY26, 57% margin' vs. delivered -9% rev, -70% PAT, 49% margin: clear miss.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
PI is navigating a severe crop-protection cycle downturn (exports -18%, PAT -70% YoY) while executing on multi-year innovation platforms (Pioxazon, pharma CDMO ₹500-600 Cr, biologicals). Gross margin guidance was implicitly cut (57% → 49%), and prior 'FY27 better than FY26' is contradicted. The company has real differentiation via its NCE pipeline and CDMO buildout, but near-term margin recovery is 2-3 years away, not H2 FY27.
₹1701.8 Cr
Revenue · −9.1% YoY₹122.2 Cr
Reported PAT · −70.1% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Domestic agri delivered 19% YoY growth
METConfirmed as strong quarter despite industry headwinds; biologicals within agri up 45%
AgChem exports held ground via volume optimization post-generics
MISSExports declined 18% YoY; volume down 3-4%, cost/pricing down balance; contradicts 'held ground'
Gross margin normalization at 47%-48%, targeting 50%-52%
OVERSTATEDDelivered OPM 13.7% (gross ~49% per mgmt); prior guidance was 57% FY26 levels; target is lower than prior
FY27 will be better than FY26 via H2 export recovery
OVERSTATEDQ2 PAT -70% YoY; first half likely deeply negative; H2 recovery assumed but unproven
New molecules at 16%-18% of AgChem exports, driving margin
METNewly commercialized molecules verified as 16-18% mix; helping but insufficient vs pricing/cost headwinds
Earnings quality
What changed since the last call
Gross margin target cut
DowngradeWas: maintain 57% (FY26 level). Now: 48-49% actual, normalized target 50-52%. Structural headwind from generics faster than expected + input cost inflation.
Export trajectory flipped
DowngradeWas: 'H2 export recovery' assumed in FY27 guidance. Now: exports -18% in Q2, attributed to market generics, RM price normalization. No near-term recovery telegraphed.
PAT decline severity
DowngradeWas: 'FY27 better than FY26'. Delivered: -70% PAT YoY. Operating leverage compressed by overhead growth in new businesses (pharma, biologicals startup losses ~$10M).
New molecule commercialization on track
UpgradePioxazon (NCE) registered in India, expanding to other geographies; 20+ molecules commercialized in 3-5 years confirms innovation pipe. But market timing headwind delays monetization.
Biologicals platform gaining traction
UpgradeGlobal biologicals +250% YoY; now expanding to Brazil, Mexico, US. Domestic biologicals +45% within domestic agri. Structural tailwind, but investments are loss-making near-term.
The Q&A
Analysts pressed hard on margin normalization (is 50%-52% structural or cyclical?), Pioxazon peak potential (quantified as potentially $300-400M market in 3-5 years but mgmt hedged), and pharma CDMO timeline (management said 2-3 years to breakeven, 3-4 to full scale, but vague on absolute revenue). Management held firm on long-term conviction but acknowledged near-term headwinds won't lift in next 1-2 quarters.
New molecule contribution — Rohit Nagraj, 360 ONE
Answered16-18% of AgChem exports; can vary quarter to quarter but ~16-18% on yearly basis.
AgChem export decline — Abhijit Akella, Kotak Institutional Equities
AnsweredVolume down 3-4%, balance (13-14%) is pricing and cost pressure. Pricing pressure primarily El Niño impact and generics.
Gross margin normalization — Abhijit Akella, Kotak Institutional Equities
Partial47%-48% currently; normalizing to 50%-52% if external pressures ease. Last 2 years exception due to cost optimization play.
New business investment costs — Tejas Pradhan, Citi
AnsweredBroadly Rs. 609 Cr vs. Rs. 530 Cr last year; Rs. 70 Cr increment; 6% of costs attributable to development and energy. Plant healthcare losses ~$10M.
Pharma CDMO target — Charul Agrawal, Bank of America
AnsweredYes, that is our target. We continue to work on that.
Plant healthcare inflection — Tarang Agrawal, Old Bridge Asset Management
PartialIn the next 2-3 years, we should be well at the inflection point. One, give EBITDA positive and the growth numbers come to stable state.
Pioxazon market sizing — Darsita Shah, DSP Asset Managers
PartialPotentially USD 300-400M range in 3-5 years, but not holding to that number. Will evaluate at ground level as first step of commercialization.
Electronics segment ramp — Ram Arvind, iThought PMS
PartialTargeting USD 100M business in 3-4 years. Early shoots visible; Udaipur kilo lab operational by year-end.
Pricing pressure on core products — Ankur Periwal, Axis Capital
PartialPressures from both consumption pattern and pricing cost economics; adaptability gets slow. But when farm economics change, they could accelerate up to 100% of everything.
Contract asset visibility — Ram Arvind, iThought PMS
AnsweredContract assets at Rs. 700 Cr odd; expected to stay at same level. Represent committed purchase orders for patented innovator product.
Guidance
FY27 +H2 export recovery (implied prior)
LowQ2 exports -18% YoY; no near-term recovery signaled. H2 assumes generics + RM inflation normalize; unproven.
Domestic agri +19% trajectory to continue
MediumQ2 delivered 19%; biologicals +45% subset. Exposed to monsoon/season variation; continued differentiation key.
Gross margin 50%-52% normalized level
MediumCurrently 49% (Q2); assumes RM inflation eases, generics pricing stabilizes. Last 2 years were exception via cost optimization.
EBITDA 14% (Q2 level)
MediumCyclical trough; recovery dependent on volume uptake post-generics + export stabilization.
Pharma CDMO platform capex: Hyderabad, Lodi, kilo lab by FY27 end
HighHyderabad center up, Lodi QC commissioned, Udaipur kilo lab to be operational by year-end.
Biologicals expansion capex in Brazil, Mexico, US
Medium3x distribution increase; investment ongoing; early-stage ramp.
Risks the call surfaced
Cyclical downturn + structural headwinds
HighAgChem exports -18%; generics faster than expected; RM inflation +13-14%; pricing pressure on core products. Gross margin guidance cut from 57% to 49%.
New platform execution risk
MediumPioxazon (NCE), pharma CDMO, biologicals, electronics—all early-stage. Management deliberately vague on timelines and revenue. Startup losses ongoing (~$10M plant healthcare).
PAT decline risk / leverage on new investments
MediumPAT -70% YoY despite -9% revenue decline. Operating leverage collapsed. New business investments (+6% development, +2% R&D, startup losses) embedded in cost base.
Monsoon & agri-demand volatility
MediumDomestic agri +19% this quarter, but monsoon outcome and soil moisture directly impact demand. Weak monsoon in Q2 FY27 noted; Rabi season outcome critical.
Margin normalization uncertainty
MediumManagement claims 50%-52% is normalized, but last achieved 57% in FY26. If generics + pricing pressure persist, structural margin erosion could be real.
Management
Score 6/10. Strategic and long-term focused; transparent on cycle headwinds and investment thesis. But deliberately vague on quantified timelines (Pioxazon market, pharma CDMO profitability delta) to avoid guidance misses. Track record mixed: delivered 20+ molecules in 3-5 years (strong); but FY27 guidance 'better than FY26' now contradicted by -70% PAT. AgChem export decline, margin cut suggest strategy is sound but execution faces headwinds.
1 · H2 FY27, Q4
Pioxazon ramp and price stabilization if El Niño/ RM inflation eases
2 · FY28-29
Pharma CDMO inflection toward ₹500-600 Cr revenue; Lodi QC, Hyderabad center commissioned
3 · FY28-29
Biologicals platform monetization: targeting $100M in 3-4 years across Brazil, Mexico, US, India
The company has real differentiation via its NCE pipeline and CDMO buildout, but near-term margin recovery is 2-3 years away, not H2 FY27.
Recovery test after Q4's 39% profit collapse
With profits down sharply last quarter and FII exiting, PI Industries must prove stabilisation on new product traction and margin recovery in Q2.
The setup: stabilisation or further decline?
PI Industries reported a 39% year-on-year collapse in net profit to ₹200 Cr in Q4 FY26, well below analyst consensus, triggering downgrades across the board. The stock has fallen 57% from all-time highs (₹4,804) and now trades 34% below median analyst targets, raising the stakes for Q2: is this a cyclical trough with recovery underway, or a sign of deeper operational challenges? The September registration of Pioxaniliprole — India's first indigenously discovered insecticide — is a material positive that could reshape long-term growth, but the Street wants proof of margin stabilisation and revenue resilience first.
What to expect in Q2
~₹350–370 Cr
on-plan trajectory; depends on formulations mix, pipeline momentum, and pricing realisations
18–22%
swing factor — Q4 pressure signals input-cost headwinds or volume deleveraging; recovery here defines tone
₹35–45 Cr
watch closely — Q4's ₹200 Cr miss flagged cost pressures; stabilisation vs extension matters
A strong Q2 would show: revenue at or above ₹360 Cr, EBITDA margin recovering to 21%+, net profit ₹40+ Cr, and management commentary confirming early Pioxaniliprole traction. A weak Q2 would signal: revenue below ₹350 Cr, margin further compressed, profit below ₹35 Cr, and no visibility on new-product monetization — extending the downtrend and validating recent FII outflow.
On track with guidance?
Unconfirmed. Management's prior FY27 guidance has not been formally reset post-Q4 decline, though the scale of the miss suggests downside revisions are likely. Q1 FY27 results (announced Aug 11) will set a run-rate baseline, but the Q4 miss raises questions about full-year assumptions. The Pioxaniliprole registration in September is strategically significant — it positions PI as an agrochem innovator in addition to a formulator — but ramp timing and contribution in FY27 remain unclear. Management must articulate: (1) whether Q4 was cyclical or structural, (2) FY27 full-year revenue/margin targets, and (3) Pioxaniliprole ramp schedule and market opportunity.
What the Street says
Since Q1 FY27 — recent filings & events
Sep 21
Pioxaniliprole registration approved (insecticide, indigenously discovered)
Material positive — opens new revenue stream; validates R&D capability
Oct 19
PI Foundation incorporation (wholly owned subsidiary, Udaipur)
Likely CSR/strategic entity; routine filing; no operational impact flagged
Oct 27
Board meeting announcement for Nov 4 result approval
On schedule; trading window closed Sep 25 (routine); no insider activity flagged
Ownership trends: FII stake fell from 16.97% (Q1 FY26) to 14.83% (Q1 FY27) — a 204 bps outflow on Q4's profit miss and near-term weakness. DII holdings stable at 31.64%. Promoter unchanged at 46.09%. The FII exit underscores caution on near-term earnings recovery.
Key watch items for result day (Nov 4)
1 · Revenue & margin stabilisation
Does Q2 show revenue back on trajectory (₹360+ Cr) and EBITDA margin recovery (21%+)? A miss here (₹350 Cr or <18% margin) extends the downtrend and validates FII skepticism. A beat resets sentiment toward the ₹3,020 target.
2 · Pioxaniliprole early traction & ramp visibility
What are initial sales, market uptake, and full-year contribution expectations? Management's confidence in monetization timeline (Q2, Q3, or delayed?) will drive the long-term narrative. Lack of detail keeps consensus cautious.
3 · FY27 full-year guidance reset
Will management reaffirm pre-Q4 targets or revise lower? A reset lower validates near-term caution but may unlock upside to FY28 growth. Flat or bullish guidance would support the ₹3,020 consensus; a downside revision extends the HOLD rating.
PI Industries enters Q2 in the doghouse: Q4's 39% profit collapse, FII selling, and a 57% peak-to-trough decline have created a wide credibility gap between the Street's ₹3,020 median target and the stock's ₹2,055 reality. The Pioxaniliprole registration is genuine innovation upside, but it's also a longer-term story — the immediate test is whether the company can stabilise margins, defend revenue, and prove that Q4 was cyclical, not structural. Nov 4 will tell whether this is the inflection point or if further pain awaits.